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Abstract
Background: Effect of post- load glucose spike (PGS), the difference between 2-hour
post-load (2h-PG) and fasting plasma glucose (FPG), on post-MI prognosis in non-diabetic
patients is unexplored.
Method: Retrospective cohort analysis of 847 non-diabetic post-MI survivors who underwent
pre-discharge oral glucose tolerance test (median PGS: 2.4 mmol/l). Patients, divided into
unmatched Groups 1 and 2 (PGS ≤ and >2.4 mmol/l) and propensity score matched
Groups 1M and 2M (355 pairs assembled from the overall cohort) were compared. Major
adverse cardiac events (MACE: death and non-fatal reinfarction) were recorded during
follow up (median: 3.4 yrs). Event freesurvival was compared by Kaplan–Meier method.
Multivariate Cox proportional hazard regression determined predictors of MACE.
C-statistics (δAUC), continuous net reclassification improvement (NRI>0) and integrated
discrimination index (IDI) were used to compare models.
Results: MACE was higher in Groups 2 (27.3% v 14.2%, p<0.001) and 2M (24.5% v 15.5%,
p<0.001). Event free survival was worse in Groups 2 (HR 2.01, 95% CI 1.49 to 2.71,
p<0.001) and 2M (HR 1.63, 95% CI 1.17 to 2.27, p=0.004). PGS independently predicted
MACE free survival in the whole (HR 1.16, 95% CI 1.06 to 1.26, p=0.002) and matched
cohort (HR 1.12, 95% CI 1.02 to 1.24, p=0.021). PGS, but not FPG or 2h-PG, improved the
predictive performance of base model (δAUC 0.013, p=0.046) with greater improvement
seen when PGS was added compared to 2h-PG (δAUC 0.005, p=0.034, NRI>0 0.2107,
p=0.013, IDI 0.0042, p=0.046).







1. The first study to suggest that post-load glucose spike (PGS) defined as the
difference between 2 hour post-load and fasting glucose measured after MI is
robust enough to predict post MI prognosis in patients without known or newly
diagnosed diabetes.
2. In patients without diabetes, PGS is a stronger determinant
of post-MI prognosis than 2-hour post-load glucose.
Keywords:
Diabetes mellitus, Oral glucose tolerance test, Myocardial infarction, Acute
coronary syndrome, Glucose spike, Glucose excursion
Background
The adverse effect of post-load glucose on post-MI prognosis in patients with newly
diagnosed diabetes mellitus (NDM) or pre-DM (pDM) is well established.1-16However, the
effect of post- load glucose spike (PGS), defined as the difference between fasting (FPG)
and 2-hour post-load plasma glucose (2h-PG), on post-MI prognosis in non-diabetic
patients has not been studied. The adverse prognostic effect of PGS in non-diabetic
population was suggested in the Diabetes Epidemiology: Collaborative Analysis of
Diagnostic Criteria in Europe (DECODE)study17 where the number of deaths in patients
increased as the difference between the fasting and 2h-PG increased. PGS, but not FPG or
HbA1c, in non-diabetic subjects is positively associated with extent and progression of
atherosclerosis 18-22, coronary plaque and plaque vulnerability. 23-27
 
Glycaemic variability (GV), that has been used to characterise hyperglycaemic spikes or
‘excursions’ especially following meals using continuous glucose monitoring (CGM) or self
monitoring of blood glucose (SMBG) adversely affected post-ACS prognosis in some 28-31 but
not other studies.32-34 A third to two-thirds of the patients included in these studies had
diabetes mellitus (DM), a group where post-ACS prognosis is already known to be worse
than in those without. GV is not identical to PGS, measuring it is cumbersome; requiring
specialised equipment for CGM or frequent needle pricks for SMBG and denotes relative
variability in blood glucose and not the absolute magnitude of glycaemic spikes. Such
monitoring can only be justified in patients with known DM or at least admission
hyperglycaemia to assist clinicians in titrating therapies and where monitoring
hypoglycaemia is as important as hyperglycaemia. Its use only to determine post-ACS
prognosis in patients without diabetes is difficult to argue for. We undertake this study to
assess whether a single measure of post-challenge glucose spike is robust enough to




We retrospectively analysed data on consecutive MI survivors not known to have DM
discharged from our institution between November 2005 and October 2008 who underwent
pre-discharge oral glucose tolerance test (OGTT), collected for the Myocardial Infarction
National Audit Project. A standardised dataset that included age, gender, risk factors for
coronary artery disease (CAD), past medical history including history of previous MI and
revascularisation, all medications, troponin I, haemodynamic status, creatinine level,
presence of heart failure and ECG changeswas analysed. The Global Registry of Acute
Coronary Events (GRACE) risk score (GRS) for mortality and re-infarction up to 6months
post-discharge was calculated using a web-based calculator. Patients underwent routine
OGTT on or after 3 days of admission. FPG was measured after ≥8 hours of overnight
fasting and 2h-PGwas measured 2 hours after administration of 75g glucose in 200 ml water.
Patients who did not tolerate or refused OGTT and those transferred to others centres
before OGTT were not considered for the study. Patients with pre-DM were advised lifestyle




MI was defined according to the universal definition.35 Diabetes was labelled as “known” if the
patient gave a history, it was recorded in there medical notes or was on treatment. Patients
without “known diabetes” were not screened with HbA1c as not recommended at the time of
data collection.36-38 All the patients with NDM (FPG ≥ 7.0 and/or 2-h PG ≥ 11.1 mmol/l) were
excluded from the analysis. The rest of the patients with NGT: FPG <6.1 mmol/l and 2-h PG
<7.8 mmol/l, IFG: FPG 6.1-6.9 mmol/l and 2h-PG <7.8 mmol/l and IGT: FPG <5.6 mmol/l and
2h-PG 7.8-11 mmol/l patients were included in the study. The post-glucose spike (PGS) was
defined as the difference between the 2h-PG and FPG. The study population was divided
into two groups; Group 1: PGS ≤ median PGS (2.4 mmol/l) and Group 2: PGS > 2.4
mmol/l. To mitigate the differences in the baseline characteristics that are likely to affect
prognosis of the patients, propensity score matching was used to assemble a paired cohort
of patients in the two groups (Group1M and Group2M) with similar baseline characteristics. 
 
Follow up
Hospital and general practice patient records were manually checked for the first occurrence
of major adverse cardiovascular events (MACE) defined as death or non-fatal re-infarction,
over the follow up period of 5 years (median 3.4 years). Completeness of follow up
was carefully ensured by manual review of hospital and general practice records. Mortality
data was verified from the general practice records linked to the national death
registry.  The East Yorkshire and North Lincolnshire Research Ethics Committee waived the
need for formal ethical approval and patient consent as this was a retrospective analysis of
routine data collected for the national audit.9
 
Statistics
Continuous variables are presented as medians (inter-quartile range, IQR) and categorical
variables as counts and proportions. The baseline characteristics in the patients in the
Groups were compared with Mann-Whitney test for continuous variables and chi-squared
test for categorical variables. Kaplan–Meier method and log-rank test was used to compare
the event free survival. Regression models were adjusted for covariates in the conventional
fashion for the “overall” analysis for the whole cohort. Logistic regression was used to
compare the incidence of MACE in the two groups. Multivariate Cox proportional hazard
regression modelling was used to analyse the effect of several variables on event free
survival. The base modelincluded the following co-variates: gender, smoking status,
hypercholesterolaemia, hypertension, history of previous acute MI, diagnosis at discharge,
discharge prescription of aspirin, clopidogrel, beta-blockers, angiotensin-converting enzyme
inhibitors and statins, inpatient revascularization status and GRS for 6months from discharge
for death and MI. Variables already included in the GRS were not included separately.
Hazard ratios with associated 95% confidence intervals (CIs) are reported. Any covariate
with variance inflation factor (VIF) >4 (MedCalc Statistical Software version
17.0.4, Ostend, Belgium), were not included in the same model to avoid the effect of
multicollinearity. 2h-PG and PGS (VIF 9.8 in the whole cohort) were not included in the same
model.
 
Logistic regression models, created by adding PGS, 2h-PG and FPG individually and in
combinations to the base model, were used to calculate predicted probabilities of MACE for
each subject. Improvement in the predictive performance of the restricted models on addition
of a covariate was examined from these predicted probabilities using different tests of
improvement in discrimination: increase in the area under the receiver operating
characteristic curve (AUC) (MedCalc Statistical Software version 17.0.4, Ostend, Belgium),
category-free continuous net reclassification index (cNRI>0) and integrated discrimination
improvement (IDI). Without pre-defined clinical risk thresholds for the models categorical NRI
was not used. The event (NRIe) and non-event NRI (NRIne) are the net percentage of
patients with and without MACE correctly assigned a higher and lower predicted risk by the
newer model with the added covariate, respectively. The overall NRI is the sum of the net
proportions of individuals with and without MACE correctly assigned a different predicted risk
and is reported as a number. The IDI is defined as the mean difference in predicted risks
between those with and without events.
 
Propensity-matching was done for the matched part only. Propensity scores were
computed for the whole cohort from above logistic regression models using all the covariates
included in the base models except the glycaemic matrices. Bipartite matching with 1:1 ratio
was performed using greedy algorithm with a fixed calliper to construct a paired cohort of




After exclusion of 206 patients with newly diagnosed DM, 847 patients were included in the
study, of which 469(55.4%) had NGT, 6 IFG, 23 IFG combined with IGT and 349 isolated
IGT. PGS was 1.5 (IQR 0.8 to 2.1) in the NGT group, and 4.0 (IQR 3.3 to 5.0) in the pDM
group. The median PGS for the entire cohort was 2.4 mmol/l (95% CI 2.3 to 2.6). There were
430 patients in Group 1 (PGS≤2.4 mmol/l) and 417 in Group 2 (PGS>2.4
mmol/l). The matched groups had 355 patients each with PGS ≤2.4 mmol/l (Group 1M) and
PGS >2.4 mmol/l (Group 2M). The median PGS for Group1M was 1.3 mmol/l and Group 2M
was 3.9 mmol/l. The baseline characteristics of the whole and the matched cohort are
presented in Table 1. 
 
Outcomes
During a median follow up of 3.4 years, MACE was higher in Group 2 compared to Group 1,
both in the unmatched and matched groups (Table 1). Event free survival was lower in group
2 and 2M than in group 1 and 1M respectively (Fig 1). Group 2 (HR 1.75, 95% CI 1.26 to
2.42, p<0.001) and 2M (HR 1.70, 95% CI 1.21 to 2.41, p=0.003) independently predicted
MACE. PGS, as a continuous variable was a predictor of MACE free survival when adjusted
for several covariates for the unmatched and matched groups (Table 2). With every mmol/l
increase in PGS, there would be a 16% and 12% increase in the probability of MACE (Table
2).
 
The c-statistic of the base model increased from 0.744 (95% CI 0.713 to 0.773) to 0.757
(95% CI 0.727 to 0.786) on addition of PGS, δAUC 0.013, p=0.046 but not on addition of
FPG  0.747, (95% CI 0.716 to 0.776), δAUC 0.003, p=0.143 or 2h-PG 0.752 (95% CI 0.722
to 0.781), δAUC=0.008, p=0.146.The c-statistics was higher when PGS was added
to the base model compared to when 2h-PG was added, δAUC 0.005, p=0.034. Addition of
PGS to models containing only GRS or GRS and FPG, in association with other co-variates
improved their predictive performance as measured by NRI>0 and IDI (Table 3). Within
the whole cohort, PGS improved net reclassification by 28% when added to the model
containing GRS only. Addition of PGS to the model containing GRS and FPG resulted in net
reclassification improvement of 25.5%. Discrimination improved in a similar pattern. These
improvements were not seen with addition of FPG. There was a greater improvement in the
predictive performance of the base model when PGS was added to it compared to when
2h-PG was added (NRI>0 0.2107, p=0.013, IDI 0.0042, p=0.046). This suggests that PGS is a
more powerful indicator of post-MI prognosis that 2h-PG itself.
 
Discussion
Several studies report worse post-MI prognosis in patients with newly diagnosed DM and
pre-diabetes1-16 with the 2h-PG being a better predictor than FPG.9;12;15;16The relation between
post-challenge glucose spike and post-MI prognosis in patients without known or newly
diagnosed DM had not been studied. This is the first study to suggest that post-load blood
glucose spike is an independent determinant and a better predictor of post-MI prognosis
in these patients.
 
The effect of post-glucose spike defined as the difference between the fasting and 2 hour
post-challenge glucose levels on prognosis in non-diabetic population was suggested in the
DECODE study.17 The largest number of excess deaths occurred in individuals with
FPG ≤6.1 mmol/l and high glucose spike in terms of increase from baseline to 2-h glucose
value. The number of deaths in patients without newlydiagnosed DM increased as the
difference between the fasting and 2h-PG increased. This is the first study to suggest this in
a post-MI population. In the Diabetes Control and Complications Trial diabetic patients with
similar HbA1c treated conventionally had a higher risk of complications than those treated
intensively.39 Although extent of postprandial glycaemic excursions was speculated as a
possible cause, subsequent reanalysis explained the results by the differences in mean
HbA1c between treatment groups over time.40 In our patients PGS as a continuous variable
was a stronger predictor of prognosis than 2h-PG itself. 
 
The effect of post-MI stress on glycaemic status makes the timing of OGTT
relevant.  Glucometabolic abnormalities are overestimated when measured within the first 24
hours after STEMI.5;41;42 However, the stress response subsidesbetween 2-5 days with no
further decrease thereafter.43 OGTT results are more reproducible in patients with
subendocardial rather than transmural infarctions.44OGTT in this study was done ≥ 3
days after admission and 55% of our patients had NSTEMI. Thus the glucose
measurements are likely to be reproducible. More importantly, as PGS is the difference
between 2h-PG and FPG, both of which are increased by
stress, PGS unlikely to have been overestimated. This may be an advantage of measuring
PGS rather than 2h-PG to mitigate the effect of stress on the glycaemic matrices.  
 
Glycaemic variability (GV) has variably been implicated in adverse post-MI outcomes. MAGE
during the first 72 hours of admission predicted MACE in anelderly ACS population 54% of
whom had DM.28 In STEMI patients with and without DM undergoing primary PCI, MAGE
was associated with short term MACE.29;30 in another study, MAGE predicted post-ACS
events only by marginal significance driven solely by its effect on events in patients with DM
and did not improve the predictive performance of models not containing MAGE.31 In a large
cohort of STEMI and NSTEMI patients, 38% of whom had DM, none of the GV matrices
during first 48 hours of hospital admission was associated
with overall adjusted in-hospital mortality. GV was associated with mortality in STEMI but not
NSTEMI patients.32 In the Diabetic Patients With Acute Myocardial
Infarction study, prognsis did not relate to GV in DM patients with AMI treated with insulin
infusion.33 In patients with DM, GV did not predict post-MI mortality.34
 
GV is not identical to PGS. GV refers to fluctuation in glucose levels, typically characterized
by hyperglycaemic spikes or ‘excursions’ following meals and quantified, as the standard
deviation of plasma glucose levels, the interquartile range, or the mean amplitude of
glycaemic excursion (MAGE). Measuring GV is cumbersome; requiring specialised
equipment for continuous glucose monitoring (CGM) or frequent needle pricks for self
monitoring of blood glucose (SMBG). This may be justified in the patients with DM where
therapy tailored to the daily variations in blood glucose is required. This is not an appropriate
test in patients without DM to assess their post-MI prognosis. MAGE only yield data about
relative variability in blood glucose and not the absolute magnitude of glycaemic spikes. Our
data suggests that in patients with known or newly diagnosed DM, the amplitude of a single
post-load glucose spike is sufficient to predict post-MI prognosis negating the need for GV
measurements. 
 
PGS, defined as the difference between the 2 hour post-load and fasting glucose level
during OGTT, adversely affects atherosclerosis. PGS, but not FPG or HbA1c, is positively
associated with carotid intima-media thickness, after adjustment for other co-variates, both in
patients without 19-22 and with DM.45 Progression of coronary atherosclerosis in non-diabetic,
non-glucose-intolerant patients with coronary artery disease is associated with 2-hour post
challenge glucose peak but not fasting glucose.18 Glucose spikes can accelerate
atherosclerotic lesion formation in non-diabetic mice model exposed to repetitive glucose
infusion.46;47High GV, after ACS, has been associated with progression of coronary




The study is limited by its retrospective observational design. This has been partially
mitigated by comparing matched groups. Although every effort was made to ensure
completeness of the data from hospital and general practice databases informationrecorded
incompletely could not be used. Exclusion of a small number of patientsthat could not have
the OGTT and mainly Caucasian study population could affect the generalizability of the
results. All patients with known or newly diagnosed DM were excluded. Even without the use
of admission HbA1c, undiagnosed DM is unlikely to have been missed using OGTT. Thus it
is certain that the study cohort does not inadvertently include DM patients. Indicators of
metabolic syndrome e.g. anthropometric measurements, assessment of insulin resistance
etc. were not available and could have changed during the follow-up. OGTT was not
repeated post-discharge. There is a possibility that patients may have crossed over between
the two compared groups. However, the KM curves remain uniformly separated throughout
follow up suggesting that the hazard assumption for the Cox analysis was proportional and
therefore this is unlikely to have affected the results. As pre-DM is associated frequently with
metabolic syndrome, in the absence of anthropometric measurements and other risk factors,
it is unclear whether this affected outcomes. 
 
Conclusion
In patients without known or newly diagnosed DM, post-load glucose spike is a determinant
of post-MI. The post-load glucose spike is a stronger determinant of prognosis than 2-hour
post-load glucose. This has important clinical implications. Firstly, to adequately
prognosticate post-MI patients without diabetes, FPG alone is inadequate and 2h-PG is
needed. Secondly, a single post-load glucose spike may obviate the need for cumbersome
measurement of glycaemic variability that is very difficult to justify in non-diabetic patients.
Thirdly, lifestyle interventions may have to be implemented in patients with high PGS even
with normal glucose tolerance to prevent the development of diabetes. And finally, trials of
SGLT2 inhibitors and GLP-1 receptor agonist may be needed to assess where blunting the
PGS would improve post-MI prognosis.
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Figure 1. Kaplan-Meier curves showing survival free of MACE in the unmatched (A) and
matched (B) Groups divided by the median post-load glucose spike in each cohort. Group 1








































Male n (%) 294(68.4) 311(74.6) 0.046 237(66.8) 269(75.8) 0.008
Current smoker n (%) 166(38.6) 134(32.1) 0.049 126(35.5) 121(34.1) 0.693
Hypertension n (%) 141(32.8) 171(41.0) 0.013 127(35.8) 133(37.5) 0.640
Hypercholesterolaemia n (%) 87(20.2) 101(24.2) 0.163 71(20.0) 82(23.1) 0.315
Previous AMI n (%) 58(13.5) 86(20.6) 0.006 52(14.7) 52(14.7) 1.000
Previous revascularisation n
(%) 29(6.7) 41(9.8) 0.103 23(6.5) 25(7.0) 0.765
Previous PVD n (%) 16(3.7) 14(3.4) 0.775 11(3.1) 12(3.4) 0.832
Previous CVA n (%) 13(3.0) 20(4.8) 0.183 9(2.5) 13(3.7) 0.386
Normal LVEF 364(84.6) 341(81.8) 0.262 299(84.2) 295(83.1) 0.685
Diagnosis NSTEMI n (%) 249(57.9) 218(52.3) 0.099 205(57.7) 185(52.1) 0.131
Discharge Medications       
  Aspirin n (%) 418(97.2) 393(94.2) 0.033 345(97.2) 338(95.2) 0.169
  Clopidogrel n (%) 396(92.1) 367(88.0) 0.047 283(79.7) 284(80.0) 0.925
  Beta-blocker n (%) 310(72.1) 311(74.5) 0.413 254(71.6) 270(76.1) 0.172
  ACEI/ARB n (%) 332(77.2) 335(80.3) 0.266 274(77.2) 288(81.1) 0.196
  Statin n (%) 373(86.7) 357(85.6) 0.633 309(87.0) 304(85.6) 0.585
GRACE variables       







Heart rate bpm (median, IQR) 75(25) 74(26) 0.707 76(25) 74(25) 0.427
SBP mmHg (median, IQR) 139(32) 138(39) 0.506 139(32.0) 138(38.0) 0.477
Creatinine µmol/l





Heart failure n (%) 15(3.5) 20(4.8) 0.339 12(3.4) 10(2.8) 0.665
ST segment depression n (%) 295(68.6) 307(73.6) 0.108 245(69.0) 266(74.9) 0.079
Troponin rise n (%) 429(99.8) 413(99.0) 0.168 355(100.0) 352(99.2) 0.083
Cardiac Arrest n (%) 14(3.3) 18(4.3) 0.418 11(3.1) 17(4.8) 0.247




1 109(39.3) 113(35.7) 0.196
Admission-6m Death/MI
(median, IQR) 157(47.0) 167(50.0)
<0.00




1 112(40.0) 116(35.0) 0.0138
Discharge-6m Death/MI
(median, IQR) 113(37.0) 123(48.0)
<0.00
1 113(37.0) 113(37.0) 0.250
Glucose levels       
  FPG (mmol/l) (median, IQR) 4.9(0.6) 5.0(0.7) 0.003 4.9(0.6) 5.0(0.7) 0.122
  2h-PG (mmol/l) (median, IQR) 6.25 (1.5) 9.0(2.0) <0.001 6.3(1.4) 8.9(2.0)
<0.00
1






  NGT  n (%) 408(94.9) 61(14.6) <0.001 337(94.9) 51(14.4)
<0.00
1
MACE n (%) 61(14.2) 114(27.3) <0.001 55(15.5) 87(24.5) 0.003
  Deaths n (%) 25(5.8) 60(14.4) <0.001 32(9.0) 44(12.4) 0.145
  Re-infarctions n (%) 36(8.4) 54(12.9) 0.031 23(6.5) 43(12.1) 0.010
AMI, Acute myocardial infarction; PVD, peripheral vascular disease; CVA, cerebrovascular
accident; LVEF, left ventricular ejection fraction; NSTEMI’ non-ST elevation myocardial
infarction;  ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker;
GRACE, Global Registry of Acute Coronary Events; IQR, interquartile range; HR, heart rate;
SBP, systolic blood pressure; FPG, fasting plasma glucose; 2HBG, 2 hour plasma glucose;
NGT, normal glucose tolerance; MACE, major adverse cardiovascular events.
 
Table 2.. Predictors of major adverse cardiovascular events. 
 Whole Cohort Matched Cohort
Covariate HR 95% CI P HR 95% CI P
Discharged without Aspirin  1.77 1.02 to 3.06 0.043 1.56 0.81 to3.03 0.182
Discharged without
clopidogrel 1.58 1.03 to 2.42 0.035 1.98
1.17 to
3.34 0.012
GRACE Score 1.01 1.01 to 1.01 <0.001 1.01 1.01 to1.02 <0.001
Previous AMI 1.95 1.29 to 2.94 0.001 1.88 1.16 to3.05 0.010
Hypercholesterolaemia 0.67 0.45 to 0.99 0.043 0.66 0.43 to1.02 0.063
Post load glucose spike 1.16 1.06 to 1.26 0.002 1.12 1.02 to1.24 0.021
The full model included gender, smoking status, hypercholesterolaemia, hypertension,
history of previous acute MI, diagnosis at discharge, discharge prescription of aspirin,
clopidogrel, beta-blockers, angiotensin-converting enzyme inhibitors and statins, inpatient





Table 3. Net reclassification index and integrated discrimination index for model




T  TOTAL p 
GRS v GRS+FPG
UP 93 331 424  
DOWN 82 341 423  
TOTAL 175 672 847  
NRI 0.0628 0.0149 0.0777 0.3597
GRS v GRS+PGS
UP 93 263 356  
DOWN 82 409 491  
TOTAL 175 672 847  
NRI 0.0628 0.2173 0.2801 <0.0001
GRS+FPG v GRS+FPG+PGS
UP 90 260 350  
DOWN 85 412 497  
TOTAL 175 672 847  
NRI 0.0286 0.2262 0.2548 0.0027
     
 IDIe IDIne IDI p
GRS v GRS+FPG
 0.00022 -0.00004 0.00026 0.8143
GRS v GRS+PGS
 0.00736 -0.00189 0.00925 0.0299
GRS+FPG v GRS+FPG+PGS
 0.00766 -0.00197 0.00964 0.0260





NRI, net reclassification index; UP, number of patients with and without event whose probability of
MACE increased with adding a variable to the restricted model; DOWN, number of patients with and
without event whose probability of MACE decreased with adding a variable to the restricted
model;  IDIe, integrated discrimination index event; IDIne, integrated discrimination index non-event.
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